Novo Nordisk to pay $2 billion for new weight loss drug
Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...
Novo Nordisk shares slide 6% after weight loss drug trial disappoints
Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, helped obese or overweight adult patients with type 2 diabetes reduce their ...
Roche signs $5.3 billion deal with Danish obesity drugmaker, Novo Nordisk stock slides 4%
Roche (RHHBY) is increasing its investment into the obesity space with an up to $5.3 billion deal with Danish drugmaker Zealand Pharma (ZLDPF), the companies announced Wednesday. The deal would give ...